Journal of Heart and Lung Transplantation最新文献

{"title":"Combined multimodal therapy in high-risk patients with chronic thromboembolic pulmonary hypertension and both distal and proximal lesions: A prospective observational cohort study","authors":"J.N. Andarelli ,&nbsp;J. Issard ,&nbsp;T. Lacoste-Palasset ,&nbsp;I. Mallak ,&nbsp;B. Gerardin ,&nbsp;S. Dolidon ,&nbsp;D. Fabre ,&nbsp;G. Dauriat ,&nbsp;T. Genty ,&nbsp;D. Mitilian ,&nbsp;O. Mercier ,&nbsp;M. Jevnikar ,&nbsp;X. Jaïs ,&nbsp;M. Humbert ,&nbsp;P. Brenot ,&nbsp;E. Fadel","doi":"10.1016/j.healun.2025.08.011","DOIUrl":"10.1016/j.healun.2025.08.011","url":null,"abstract":"<div><h3>Background</h3><div>Treatments for chronic thromboembolic pulmonary hypertension (CTEPH) include PH-specific pharmacotherapy (PHSP), balloon pulmonary angioplasty (BPA), and pulmonary endarterectomy (PEA). We evaluated a sequential multimodal strategy (SMS) combining PHSP, BPA, and PEA in selected high-surgical-risk patients with distal lesions in one lung and proximal lesions in the other.</div></div><div><h3>Methods</h3><div>In this prospective observational study, patients were selected to the SMS by a multidisciplinary panel, based on hemodynamic severity, location of lesions, and comorbidity profile. Characteristics and complications of procedures were collected. Clinical, laboratory, and hemodynamic data were compared at baseline, before BPA, before PEA, and 6 months after PEA.</div></div><div><h3>Results</h3><div>We enrolled 61 patients, aged 61.9 ± 13.0 years, between 2017 and 2023. At baseline, mean pulmonary artery pressure (mPAP), cardiac output (CO), and pulmonary vascular resistance (PVR) were 49.0 ± 11.7 mmHg, 4.3 ± 1.2 L/min and 9.9 ± 4.0 WU, respectively. The most common complications were hemoptysis (13.1%) and pulmonary artery dissection (6.5%) for BPA and acute kidney injury (34.4%) and reperfusion pulmonary edema (31.1%) for PEA. The New York Heart Association functional class improved significantly and mPAP and PVR decreased significantly after each step of the strategy. Compared to baseline, the mPAP decrease was −49.4% ± 16.7% and the PVR decrease was −69.3% ± 15.9%. Three patients died in the first 2 months following surgery. The overall survival rate 14 months after PEA was 95%.</div></div><div><h3>Conclusion</h3><div>Our multimodal strategy was safe and effective in selected patients with severe CTEPH in whom upfront PEA was deemed unacceptably hazardous due to a high surgical risk and mixed anatomical lesions.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 137-147"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluoroless bedside implantation of the ProtekDuo cannula: Clinical experience at a tertiary care center","authors":"Pasquale Nardelli MD ,&nbsp;Savino Altizio MD ,&nbsp;Evgeny Fominskiy MD ,&nbsp;Alessandro Ortalda MD ,&nbsp;Luca Baldetti MD ,&nbsp;Claudia Francescon PT ,&nbsp;Silvia Ajello MD ,&nbsp;Anna Mara Scandroglio MD","doi":"10.1016/j.healun.2025.09.005","DOIUrl":"10.1016/j.healun.2025.09.005","url":null,"abstract":"<div><div>The ProtekDuo dual-lumen cannula allows percutaneous support in right ventricular failure with or without gas exchange impairments. However, positioning of the device is resource demanding. The usual approach requires a fluoroscopy–equipped operating room, possibly limiting its wider and timely adoption. We report our initial experience with bedside, fluoroless ProtekDuo implantation under transesophageal echocardiography (TEE) guidance in a tertiary care national referral center. Eight critically ill patients underwent bedside ProtekDuo placement for right ventricular dysfunction or acute respiratory distress syndrome with right ventricular failure. All procedures were completed successfully without procedural complications. Our findings demonstrate that bedside, TEE-guided, fluoroless ProtekDuo cannulation is feasible and safe, potentially expanding access to advanced mechanical circulatory support.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 85-88"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ISHLT Statement on Vaccines in Transplant Recipients","authors":"Jennifer K. Chow MD, MD, FAST, FIDSA ,&nbsp;Neha Bansal MD","doi":"10.1016/j.healun.2025.09.006","DOIUrl":"10.1016/j.healun.2025.09.006","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 5-6"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Center experience is associated with greater survival following donation after circulatory death heart transplantation","authors":"Brian E. Woolley BS ,&nbsp;Yeahwa Hong MD, PhD ,&nbsp;Umar Nasim BS ,&nbsp;Nidhi Iyanna MPH ,&nbsp;Ander Dorken-Gallastegi MD ,&nbsp;Samantha N. Machinski BA ,&nbsp;Gavin W. Hickey MD ,&nbsp;Mary E. Keebler MD ,&nbsp;Edward T. Horn PharmD ,&nbsp;David J. Kaczorowski MD","doi":"10.1016/j.healun.2025.08.015","DOIUrl":"10.1016/j.healun.2025.08.015","url":null,"abstract":"<div><h3>Background</h3><div>Higher center volume has been associated with improved outcomes in solid organ transplantation. However, the impact of center experience on donation after circulatory death (DCD) heart transplantation outcomes remains unclear. This study evaluates the association between cumulative DCD center experience and DCD post-transplant survival.</div></div><div><h3>Methods</h3><div>The United Network for Organ Sharing registry was queried for adult recipients who underwent DCD heart transplantation from January 1, 2019 to December 31, 2023. Recipients were stratified by cumulative DCD center experience into low (≤10), intermediate (11-24), and high (≥25) transplant volume centers. The primary outcome was 1-year post-transplant survival. A restricted cubic spline (RCS) model was used to assess the volume-outcome relationship.</div></div><div><h3>Results</h3><div>A total of 1,114 DCD heart transplant recipients across 59 centers were included. Low cumulative DCD volume was associated with lower 1-year DCD post-transplant survival compared to high-volume centers when controlling for confounders (89.0% vs 92.9%, <em>p</em> = 0.025), independent of donation after brain death (DBD) center volume and center-level DBD post-transplant survival. RCS showed decreasing 1-year post-transplant mortality with increasing DCD volume up to 20 DCD cases, beyond which survival gains plateaued. Normothermic regional perfusion was associated with similar survival compared to direct procurement and perfusion across all center volume categories.</div></div><div><h3>Conclusions</h3><div>Higher cumulative DCD center experience is associated with improved 1-year DCD post-transplant survival independent of DBD center volume or performance. Survival gains plateau after approximately 20 cumulative DCD cases. These findings highlight the importance of DCD-specific institutional experience and support the expansion of DCD heart transplantation to more centers while maintaining favorable outcomes.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 47-56"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors and outcomes of severe primary graft dysfunction in heart transplantation: United States cohort analysis","authors":"Peter D. Cho BS ,&nbsp;Hedwig Zappacosta BS ,&nbsp;Joseph Song BA ,&nbsp;John P. White BA ,&nbsp;Stephanie McKay MPH ,&nbsp;Donatello Telesca PhD ,&nbsp;Malini Daniel MD ,&nbsp;Abbas Ardehali MD","doi":"10.1016/j.healun.2025.07.036","DOIUrl":"10.1016/j.healun.2025.07.036","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to assess predictors and outcomes of severe primary graft dysfunction (PGD) in a contemporary United States cohort.</div></div><div><h3>Methods</h3><div>The United Network for Organ Sharing database was retrospectively reviewed for isolated adult heart transplant recipients (September 2023-March 2025). The population was stratified into severe PGD (left or biventricular dysfunction within 24 hours following transplantation that requires mechanical circulatory support [MCS]) and control cohorts (all other recipients). Predictors of severe PGD were identified using multivariable logistic regression. The severe PGD cohort was further classified into transient severe primary graft dysfunction (TPGD, MCS off by 72 hours) vs. persistent severe primary graft dysfunction (PPGD, remained on MCS at 72 hours). The Kaplan-Meier method was used to compare 3-month survival between groups.</div></div><div><h3>Results</h3><div>During the study interval, 5,097 heart transplant recipients were identified in the United States, with 6.6% (<em>n</em> = 338) developing severe PGD. Predictors for severe PGD included pretransplant extracorporeal membrane oxygenation (adjusted odds ratio [AOR]: 2.55, <em>p</em> &lt; 0.001), hearts from donation after circulatory death (AOR: 2.13, <em>p</em> &lt; 0.001), donor acidemia before procurement (AOR: 2.01, <em>p</em> &lt; 0.001), and recipient history of sternotomy (AOR: 1.83, <em>p</em> &lt; 0.001). The severe PGD group experienced lower 3-month survival than the control group (74.4% vs 96.8%, <em>p</em> &lt; 0.001). Among severe PGD cases, 36.7% (<em>n</em> = 124) experienced TPGD and had higher 3 month survial than PPGD group (88.0% vs 67.2%, <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Severe PGD following heart transplantation is associated with high early mortality. Consideration of risk factors in donor and recipient matching may mitigate the incidence of severe PGD.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 16-25"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S1053-2498(25)02445-3","DOIUrl":"10.1016/S1053-2498(25)02445-3","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Page A2"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct oral anticoagulants in left ventricular assist devices: Where are we now?","authors":"Leticia Blazquez-Arroyo ,&nbsp;Guglielmo Gallone ,&nbsp;Luca Baldetti ,&nbsp;Mario Gramegna ,&nbsp;Thomas Castelein ,&nbsp;Riet Dierckx ,&nbsp;Francesca Fiorelli ,&nbsp;Diana Gorog ,&nbsp;Eftychia Galiatsou ,&nbsp;Haifa Lyster ,&nbsp;Sascha Ott ,&nbsp;Brijesh Patel ,&nbsp;Alex Rosenberg ,&nbsp;Dan Schelfaut ,&nbsp;Lorenz Van der Linden ,&nbsp;Jeroen Dauw ,&nbsp;Ward Heggermont ,&nbsp;Marc Vanderheyden ,&nbsp;Stijn Wouters ,&nbsp;Maria Monteagudo-Vela ,&nbsp;Christophe Vandenbriele MD, PhD","doi":"10.1016/j.healun.2025.08.025","DOIUrl":"10.1016/j.healun.2025.08.025","url":null,"abstract":"<div><div>Despite significant advances in left ventricular assist device (LVAD) technology, particularly with the HeartMate 3, hemocompatibility-related adverse events (HRAEs), especially bleeding, remain common due to complex patient-device interactions and the need for anticoagulation. This has prompted interest in exploring new and less aggressive antithrombotic strategies. Direct oral anticoagulants (DOACs) have gained attention for their predictable pharmacokinetics, fixed dosing, and lower bleeding risk in other populations. Among them, apixaban has emerged as the most extensively studied DOAC in the HeartMate 3 setting, standing out as a promising alternative to VKAs in carefully selected patients, with the potential to lower bleeding risk without compromising thrombotic protection. However, available evidence remains limited by small sample sizes, short follow-up, and selected patient populations. Important gaps persist regarding optimal dosing, timing of initiation, level monitoring, and safety in vulnerable subgroups, particularly patients awaiting heart transplantation.</div><div>This review synthesizes the current evidence on DOAC use in HeartMate 3-supported patients, provides practical guidance for real-world decision-making, and highlights areas where further research is needed. Although more data are required to define its role, apixaban is increasingly positioned as a promising VKA alternative in LVAD-patients and could ultimately reshape anticoagulation practice in this population.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 71-82"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145059121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and primary graft dysfunction after ex-vivo lung perfusion: Why timing matters","authors":"Awab Ahmad MD,&nbsp;Aaron M. Williams MD","doi":"10.1016/j.healun.2025.08.019","DOIUrl":"10.1016/j.healun.2025.08.019","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 69-70"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of evolocumab on coronary physiology and microstructure in de-novo heart transplant recipients","authors":"Salma Raghad Karim ,&nbsp;Niels Møller Jensen ,&nbsp;Emil Nielsen Holck ,&nbsp;Tor Skibsted Clemmesen ,&nbsp;Evald Høj Christiansen ,&nbsp;Lars Jakobsen ,&nbsp;Zhi Chen ,&nbsp;Milan Sonka ,&nbsp;Kristjan Karason ,&nbsp;Kaspar Broch ,&nbsp;Ole Geir Solberg ,&nbsp;Hans Eiskjær","doi":"10.1016/j.healun.2025.07.037","DOIUrl":"10.1016/j.healun.2025.07.037","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac allograft vasculopathy, characterized by arterial intima thickening and microvascular dysfunction, compromises survival after heart transplantation. We investigated the impact of evolocumab on invasive coronary physiology and microstructure after de-novo transplantation.</div></div><div><h3>Methods</h3><div>In the EVOLVD trial (NCT03734211), the effect of 12 months of evolocumab vs placebo on maximal coronary intimal thickness was assessed using intracoronary ultrasound. For this substudy, optical coherence tomography (OCT), fractional flow reserve (FFR), coronary flow reserve (CFR), microvascular resistance reserve (MRR), and index of microcirculatory resistance (IMR) were performed at baseline (4-8 weeks post-transplant) and at 12 months post-transplant.</div></div><div><h3>Results</h3><div>Seventy-five de-novo heart transplant recipients were included, randomized to placebo (<em>n</em> = 36) or evolocumab (<em>n</em> = 39). Over 12 months, no between-group differences were observed in changes in coronary physiology (FFR: Δ 0.001 [IQR −0.03 to 0.02], <em>p</em> = 0.42; CFR: Δ 0.59 [IQR −1.33 to 1.90], <em>p</em> = 0.69; IMR: Δ 0.76 [IQR −6.86 to 8.32], <em>p</em> = 0.09; MRR: Δ 0.19 [IQR −1.85 to 2.60], <em>p</em> = 0.70) or coronary microstructure (lumen area: Δ −1.37 mm² [IQR −3.53 to 0.09], <em>p</em> = 0.38; intima area: Δ 0.05 mm² [IQR 0.02 to 0.17], <em>p</em> = 0.88. Among all patients, OCT showed a lumen area decrease of −1.37 [IQR −3.53 to −0.69] mm² (<em>p</em> &lt; 0.01) and intima area increasse of 0.04 [IQR 0.01 to 0.17] mm² (<em>p</em> &lt; 0.01) from baseline to follow-up.</div></div><div><h3>Conclusions</h3><div>Evolocumab did not affect coronary physiology or OCT measurements 12 months after de-novo heart transplantation. OCT revealed progressive intimal proliferation and luminal narrowing in both groups, while coronary physiology remained unchanged and did not differ between treatment arms.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 26-36"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection","authors":"Sandrine Hirschi MD ,&nbsp;Guilaine Hell PharmD ,&nbsp;Deborah Jo Levine MD ,&nbsp;Benjamin Coiffard MD, PhD ,&nbsp;Francois Severac MD, MSc ,&nbsp;Clement Picard MD ,&nbsp;Vincent Bunel MD ,&nbsp;Jerome Le Pavec MD, PhD ,&nbsp;Arnaud Essaydi PharmD ,&nbsp;Martine Reynaud-Gaubert MD, PhD ,&nbsp;Antoine Roux MD, PhD ,&nbsp;Olivier Brugiere MD, PhD ,&nbsp;Benjamin Renaud-Picard MD, PhD ,&nbsp;Romain Kessler MD, PhD ,&nbsp;Federica Pezzuto MD, PhD ,&nbsp;Jean-Luc Taupin PharmD, PhD ,&nbsp;Fiorella Calabrese MD","doi":"10.1016/j.healun.2025.08.007","DOIUrl":"10.1016/j.healun.2025.08.007","url":null,"abstract":"<div><h3>Background</h3><div>The diagnosis of pulmonary antibody–mediated rejection (AMR) remains challenging with lack of specific defining features. This study evaluated the diagnostic and prognostic significance of intragraft anti human leukocyte antigen (HLA) donor–specific antibodies (gDSA) in pulmonary AMR.</div></div><div><h3>Methods</h3><div>This multicenter prospective study enrolled adult lung transplant recipients (LTR) with serum anti-HLA DSA (sDSA) &gt;1,000 Luminex mean fluorescence intensity (MFI). Transbronchial biopsies (TBBx) were obtained for both standard histologic analysis and cryopreservation to detect anti-HLA class I and II gDSA, using Luminex single-antigen beads assay. Clinical follow-up was conducted over 24 months. An expert pathologist reviewed all TBBx using a predefined checklist. A blinded adjudication panel categorized clinical diagnoses as possible, probable, or definite AMR and non-AMR conditions. The primary objective was to assess gDSA sensitivity and specificity for AMR diagnosis. Additionally, we compared graft outcomes between gDSA+ vs gDSA− patients.</div></div><div><h3>Results</h3><div>Seventy-seven LTR from 5 centers were included from August 2019 to July 2022. Twenty-nine patients were classified as probable or definite clinical/subclinical AMR. Among the cohort, 13 had positive gDSA. gDSA sensitivity, specificity, and positive predictive value for AMR diagnosis were 34.4%, 93.7%, and 76.9%, respectively. gDSA diagnostic performance for AMR was better than sDSA ≥12,500 MFI (sensitivity 37.9%, specificity 85.4%, and positive predictive value 61.1%). Event-free survival analysis (10% forced expiratory volume in 1 second decline or graft loss) showed no significant differences by gDSA positivity. Limited biopsy sampling and spatial heterogeneity may have biased sensitivity and prognostic performances of the technique.</div></div><div><h3>Conclusions</h3><div>gDSA might offer a specific complementary support for the clinical diagnosis of AMR following lung transplantation.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages 37-46"},"PeriodicalIF":6.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}